Parente Luca, Solito Egle
Department of Pharmaceutical Sciences, University of Salerno, Via Ponte Don Melillo, 84084 Fisciano, Salerno, Italy.
Inflamm Res. 2004 Apr;53(4):125-32. doi: 10.1007/s00011-003-1235-z. Epub 2004 Mar 18.
Annexin 1 (ANXA1) is the first characterized member of the annexin family of proteins able to bind (i.e. to annex) to cellular membranes in a calcium-dependent manner. ANXA1 may be induced by glucocorticoids in inflammatory cells and shares with these drugs many anti-inflammatory effects. Originally described as a phospholipase A2 (PLA2)-inhibitory protein, ANXA1 can affect many components of the inflammatory reaction besides the metabolism of arachidonic acid. Recent data have shown that ANXA1 may specifically target cytosolic PLA2 by both direct enzyme inhibition and suppression of cytokine-induced activation of the enzyme. ANXA1 inhibits the expression and/or activity of other inflammatory enzymes like inducible nitric oxide synthase (iNOS) in macrophages and inducible cyclooxygenase (COX-2) in activated microglia. The inhibition of iNOS expression may be caused by the stimulation of IL-10 release induced by ANXA1 in macrophages. Like glucocorticoids, ANXA1 exerts profound inhibitory effects on both neutrophil and monocyte migration in inflammation. Several mechanisms may contribute to the protein effect on cell migration, namely the activation of receptors like the formyl peptide receptor (FPR) and the lipoxin A4 receptor (ALXR), the shedding of L-selectin, the binding to alpha4beta1 integrin and carboxylated N-glycans. Furthermore, again mimicking the action of glucocorticoids, ANXA1 promotes inflammatory cell apoptosis associated with transient rise in intracellular calcium and caspase-3 activation. Finally, ANXA1 has been recently identified as one of the 'eat-me' signals on apoptotic cells to be recognised and ingested by phagocytes. Thus, ANXA1 may contribute to the anti-inflammatory signalling that allows safe post-apoptotic clearance of dead cells.
膜联蛋白1(ANXA1)是膜联蛋白家族中首个被鉴定的成员,能够以钙依赖的方式结合(即膜附着)到细胞膜上。在炎症细胞中,糖皮质激素可诱导ANXA1的产生,且它与这些药物具有许多共同的抗炎作用。ANXA1最初被描述为一种磷脂酶A2(PLA2)抑制蛋白,除了影响花生四烯酸的代谢外,它还能影响炎症反应的许多成分。最近的数据表明,ANXA1可能通过直接抑制酶活性以及抑制细胞因子诱导的该酶激活,特异性地作用于胞质型PLA2。ANXA1可抑制其他炎症酶的表达和/或活性,如巨噬细胞中的诱导型一氧化氮合酶(iNOS)以及活化小胶质细胞中的诱导型环氧化酶(COX-2)。对iNOS表达的抑制可能是由于ANXA1刺激巨噬细胞释放白细胞介素-10所致。与糖皮质激素一样,ANXA1对炎症中中性粒细胞和单核细胞的迁移均具有显著的抑制作用。该蛋白对细胞迁移的影响可能由多种机制介导,即激活甲酰肽受体(FPR)和脂氧素A4受体(ALXR)等受体、L-选择素的脱落、与α4β1整合素和羧化N-聚糖的结合。此外,同样模拟糖皮质激素的作用,ANXA1可促进炎症细胞凋亡,这与细胞内钙的短暂升高和半胱天冬酶-3的激活有关。最后,最近已确定ANXA1是凋亡细胞上可被吞噬细胞识别并吞噬的“吃掉我”信号之一。因此,ANXA1可能有助于抗炎信号传导,从而实现对凋亡细胞的安全清除。